share_log

Virpax Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933

Virpax Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933

Virpax制药 | S-1：证券上市注册声明
美股SEC公告 ·  07/29 16:37

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024, for a proposed public offering of its common stock and pre-funded warrants. The offering includes an undisclosed number of shares and pre-funded warrants, with each warrant exercisable for one share of common stock at an exercise price of $0.00001 per share. The warrants are immediately exercisable and may be exercised at any time until fully exercised. RBW Capital Partners LLC, acting through Dominari Securities LLC, has been engaged as the exclusive placement agent for the offering on a reasonable best-efforts basis. The offering is expected to close one business day following its commencement. Virpax intends to use the net proceeds from the offering to fund ongoing activities related to their planned Investigational New Drug (IND) filing for Probudur, as well as for working capital and other general corporate purposes. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX'.
Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024, for a proposed public offering of its common stock and pre-funded warrants. The offering includes an undisclosed number of shares and pre-funded warrants, with each warrant exercisable for one share of common stock at an exercise price of $0.00001 per share. The warrants are immediately exercisable and may be exercised at any time until fully exercised. RBW Capital Partners LLC, acting through Dominari Securities LLC, has been engaged as the exclusive placement agent for the offering on a reasonable best-efforts basis. The offering is expected to close one business day following its commencement. Virpax intends to use the net proceeds from the offering to fund ongoing activities related to their planned Investigational New Drug (IND) filing for Probudur, as well as for working capital and other general corporate purposes. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX'.
药品公司Virpax Pharmaceuticals, Inc.（Virpax）已于2024年7月29日向美国证券交易委员会（SEC）提交了注册声明，拟公开发行其普通股和预融资权证。拟发行的股票和预先融资权的数量尚未公开，每个权证可按每股0.00001美元的行权价格行使购买一股普通股。权证立即可行使，并可在完全行使前的任何时间行使。RBW Capital Partners LLC（通过Dominari Securities LLC代表）已被指定为该公开发行的独家配售代理，采取合理最大努力方式销售。公开发售的预计结束时间为开售后的一个工作日。Virpax拟利用发售净收益用于资助与Probudur计划新药研究相关的持续性活动，以及用于运营资金和其他一般公司用途。该公司的普通股在纳斯达克交易所上市，股票代码为“VRPX”。
药品公司Virpax Pharmaceuticals, Inc.（Virpax）已于2024年7月29日向美国证券交易委员会（SEC）提交了注册声明，拟公开发行其普通股和预融资权证。拟发行的股票和预先融资权的数量尚未公开，每个权证可按每股0.00001美元的行权价格行使购买一股普通股。权证立即可行使，并可在完全行使前的任何时间行使。RBW Capital Partners LLC（通过Dominari Securities LLC代表）已被指定为该公开发行的独家配售代理，采取合理最大努力方式销售。公开发售的预计结束时间为开售后的一个工作日。Virpax拟利用发售净收益用于资助与Probudur计划新药研究相关的持续性活动，以及用于运营资金和其他一般公司用途。该公司的普通股在纳斯达克交易所上市，股票代码为“VRPX”。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间